About the Gastrointestinal Pathogen Panel (GPP)

Gastroenteritis is caused by a variety of bacterial, viral and parasitic organisms. In 2010, the US associated cost for the 237,000+ patients suffering from gastrointestinal infections was over $6 billion. Diarrhea inflicts a significant toll on the health care system and can result in a high degree of morbidity in select populations. Diagnostically, it’s difficult to differentiate the causes of gastroenteritis due to similar symptoms; 80% of diarrhea causes are currently unidentified. Inappropriate use of therapeutics provides favorable conditions for the emergence of resistant organisms, thus necessitating more expensive therapies to treat the infection. Excelsior Diagnostics’ GPP screens for 18 bacterial, viral and pathological targets in under 24 hours, to effectively diagnose and treat gastroenterological infections.

  • 1 in 6 Americans acquire food borne diseases annually
  • There are 128,000 hospitalizations and 3,000 deaths each year, due to food borne illnesses in the US
  • Unsafe food is responsible for illness in at least 2 billion people worldwide
  • 1.9 million children globally die from diarrheal disease alone
  • 80% of food borne pathogens are unidentified, causing inappropriate antibiotic use and patient care
  • Excelsior Diagnostic’s GPP is the only test that simultaneously detects and identifies bacterial, viral and parasitic pathogens responsible for infectious diarrhea

How is the test done?

A stool sample is collected and packaged in a pre-paid UPS clinical pack and overnighted to Excelsior Diagnostics. Excelsior then processes the specimen with PCR molecular technology, with results in less than five hours. When the test is positive, the identified bacteria is automatically submitted for Antibiotic Resistance (ABR) Screening, to immediately identify the most effective antibiotic treatment.

How is that better than the standard legacy method?

Excelsior’s GPP is the most comprehensive screening panel available today. Same day results of both the culture and the Antibiotic Resistance (ABR) Panel allow health care providers to treat infections more quickly and precisely than any other screening method. 

Salmonella / Shigella / Campylobacter / Shiga Toxin 1 / Shiga Toxin 2 / Vibrio Cholera / E. Coli 0157 / E. Coli ST / E. Coli LT / C. Difficile Toxin A / C. Difficile Toxin B
Giardia Iamblia
Entamoeba Histolytica
Norovirus GI
Norovirus GII
Rotavirus A
Adenovirus 40/41

View the Complete Antibiotic Resistance Panel (ABR)

Antibiotic – Gene
  • Methicillin – mecA
  • Vancomycin – VanA1
  • Vancomycin – VanA2
  • Vancomycin – VanB
  • Quinolone and fluoroquinolone resistance – QnrA
  • Quinolone and fluoroquinolone resistance – QnrB
  • Macrolide resistance – ErmA
  • Macrolide resistance – ErmB
  • Macrolide resistance – ErmC
  • Ampicillin – ampC
  • Tetracycline – tetM
  • Carbapenem resistance – VIM
  • Carbapenem resistance – KPC
  • Carbapenem resistance – OXA-23
  • Carbapenem resistance – IMP-16
  • Carbapenem resistance – IMP-7
  • Carbapenem resistance OXA-72
  • Carbapenem resistance OXA-40
  • Carbapenem resistance – OXA-58
  • Carbapenem resistance – OXA-48
  • Carbapenem resistance – NDM
  • Beta-Lactam – blaSHV-5
  • Extended-Spectrum-Betalactamase – SHV
  • Extended-Spectrum-Betalactamase – CTX-M group 1
  • Extended-Spectrum-Betalactamase – CTX-M group 2
  • Extended-Spectrum-Betalactamase – CTX-M group 9
  • Extended-Spectrum-Betalactamase – CTX-M group 8/25

Easy & sanitary disposable GPP Specimen Collection Kits - available to ship straight to the patient's home!

Instructions for Stool Specimen Collection & Shipment


Problem: Patients need convenience and privacy with stool collection methods; Clinics are concerned about infection control.
Solution: GPP Specimen Collection Kit is either provided by the clinic or shipped directly to the patient’s home
HYStool GPP Specimen Collection Kits are now available through Excelsior.
Download & Print Instructions

Legacy Method vs. GPP

GPP legacy method GPP Excelsior DX method

*Per Journal of Infection, May 2015, Volume 70, Issue S, Pages 504-511

microscope research

A Study from Journal of Infection, May 2015

A cost-benefit analysis of the xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalized patients.



Recent advances in the laboratory detection of infectious diarrhea allow more rapid and sensitive identification of infected patients. Several commercial multiplex molecular panels are now available and may have significant advantages over culture-based techniques. Faster and more sensitive testing of hospitalized patients with suspected infectious gastroenteritis could result in significant efficiencies in the utilization of isolation facilities, however, few studies have examined this potential benefit. We studied the potential clinical and cost benefits of a commercially available molecular panel.


An eight-month parallel diagnostic study was conducted to measure potential economic benefits of testing hospitalized patients with the xTAG Gastrointestinal Pathogen Panel (GPP) compared with conventional laboratory testing (based on a combination of culture, microscopy and enzyme immunoassay). Laboratory testing costs and patient isolation costs were measured or estimated for 800 patients.


Although costing an additional $28,007.95, use of GPP could enable a reduction in isolation time from 2202 to 1447 days, a savings of $55,910.31, which more than offsets the additional laboratory testing costs.


Syndromic testing of patients against a broad panel of organisms using a multiplex molecular panel can both improve detection rates and allow better laboratory workflow practices. Removing patients testing negative using this panel could result in significant patient isolation savings.

Excelsior X white

The Excelsior Guarantee

Excelsior Diagnostics is a specialty medical diagnostic lab that performs all testing exclusively by Polymerase Chain Reaction Molecular Analysis, the most accurate diagnostic medical testing available today.